Lehrstuhl für Innere Medizin III

IMATINIB-LOADED TARGETED GOLD NANOPARTICLES AMELIORATE EXPERIMENTAL LUNG FIBROSIS INDUCED BY BLEOMYCIN (2017) Codullo V, Breda S, Meloni F, Cova E, Inghilleri S, Colombo M, Prosperi D, et al. Conference contribution EVALUATION OF FREQUENCY AND TYPE OF PHYSICAL THERAPY IN MORE THAN 3400 PATIENTS WITH SYSTEMIC SCLEROSIS (2017) Belz D, Moinzadeh P, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, et al. Conference contribution IL-17-22-23 PATHWAYS IN PSORIATIC ARTHRITIS AND PSORIASIS (2017) Nas K, Cevik R, Yildiz I, Rech J, Schett G Conference contribution ABATACEPT BUT NOT TNF INHIBITORS BLOCK AUTOANTIBODY-MEDIATED CYTOKINE PRODUCTION BY MONOCYTES (2017) Bozec A, Luo Y, Engdahl C, Figueiredo C, Bang H, Schett G Conference contribution APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution DIFFUSING CAPACITY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS (2017) Moinzadeh P, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, Schmalzing M, et al. Conference contribution Adipocytokine as a Link between Metabolism and Osteoarthritis (2017) Huelser ML, Schreiyaeck C, Luo Y, Bozec A, Schett G, Mueller-Ladner U, Neumann E Conference contribution Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis (2017) Soare A, Gyoerfy H, Matei AE, Dees C, Chen CW, Ramming A, Schett G, Distler J Conference contribution Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study (2017) Schett G, Lehman T, Ahmad HA, Johnsen A, Banerjee S, Mease PJ Conference contribution